Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
184 studies found for:    "Wilms tumor"
Show Display Options
Rank Status Study
21 Unknown  Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor
Condition: Kidney Cancer
Interventions: Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
22 Completed Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
Conditions: Clear Cell Sarcoma of the Kidney;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Rhabdoid Tumor of the Kidney;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis
23 Completed DNA Variations in the Gene in Young Patients With Wilms' Tumor
Condition: Kidney Cancer
Interventions: Genetic: molecular genetic technique;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis
24 Unknown  Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney
Condition: Kidney Cancer
Interventions: Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous bone marrow transplantation;   Procedure: conventional surgery;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
25 Completed Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor
Conditions: Kidney Cancer;   Renal Failure
Interventions: Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
26 Recruiting Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Conditions: Pleuropulmonary Blastoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Neuroblastoma;   Recurrent Rhabdomyosarcoma;   Recurrent Synovial Sarcoma;   Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Lorvotuzumab Mertansine;   Other: Pharmacological Study
27 Not yet recruiting Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Conditions: Adrenal Cortex Carcinoma;   Adult Alveolar Soft Part Sarcoma;   Adult Clear Cell Sarcoma of Soft Parts;   Adult Hepatocellular Carcinoma;   Adult Rhabdomyosarcoma;   Adult Soft Tissue Sarcoma;   Childhood Alveolar Soft Part Sarcoma;   Childhood Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Childhood Hepatocellular Carcinoma;   Childhood Rhabdomyosarcoma;   Childhood Soft Tissue Sarcoma;   Childhood Solid Neoplasm;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Hepatocellular Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Solid Neoplasm;   Renal Cell Carcinoma;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
28 Completed
Has Results
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Childhood Hepatocellular Carcinoma;   Papillary Thyroid Cancer;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Thyroid Cancer;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
29 Completed
Has Results
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Intervention: Drug: WT1 Peptide Vaccine
30 Completed Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor
Condition: Kidney Cancer
Interventions: Genetic: DNA methylation analysis;   Genetic: RNA analysis;   Genetic: allele-specific oligonucleotide real-time quantitative polymerase chain reaction;   Genetic: gene expression analysis;   Genetic: nucleic acid sequencing;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
31 Active, not recruiting A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
Conditions: Sarcoma;   Neuroblastoma;   Wilm's Tumor
Interventions: Biological: Tumor lysate-pulsed dendritic cell (DC) vaccine;   Other: Hematopoietic stem cell transplantation (HSCT)
32 Completed
Has Results
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Conditions: Leukemia, Acute Myelogenous (AML);   Leukemia, Acute Lymphocytic (ALL);   Leukemia, Chronic Myelogenous (CML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: WT1 Peptide-Pulsed Dendritic Cells;   Drug: Donor Lymphocytes;   Drug: IL-4;   Drug: KLH;   Drug: WT1 Peptides;   Drug: Endotoxin;   Drug: Diphenhydramine;   Drug: Acetaminophen
33 Completed Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
Condition: Kidney Cancer
Interventions: Biological: dactinomycin;   Biological: filgrastim;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
34 Completed Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Minimal Residual Disease;   Wilms Tumor
Intervention:
35 Recruiting WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Biological: WT1 Analog Peptide Vaccine;   Biological: Sargramostim (GM-CSF);   Drug: lenalidomide
36 Completed Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: dactinomycin;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
37 Completed WT1 for the Detection of Minimal Residual Disease
Conditions: Leukemia;   Cancer
Intervention: Procedure: WT 1 Testing
38 Recruiting WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
Conditions: Acute Myeloid Leukaemia;   Chronic Myeloid Leukaemia
Intervention: Genetic: WT1 TCR-transduced T cells
39 Completed Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors
Conditions: Wilms' Tumor;   Sarcoma;   Adenaocortical Carcinoma;   Refractory Cancer;   Coldrhood Cancer
Intervention: Drug: Tariquidar
40 Recruiting A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
Conditions: Myelodysplastic Syndromes (MDS);   Acute Myeloid Leukaemia (AML)
Intervention: Genetic: Gene-modified WT1 TCR-transduced T cells intravenous infusion

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.